Department of Surgery - Krankenhaus Reinbek St. Adolf-Stift, Reinbek, Germany.
Institut für Laboratoriums- und Transfusionsmedizin, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany.
Front Immunol. 2022 Jul 1;13:896151. doi: 10.3389/fimmu.2022.896151. eCollection 2022.
Since the introduction of various vaccines against SARS-CoV-2 at the end of 2020, infection rates have continued to climb worldwide. This led to the establishment of a third dose vaccination in several countries, known as a booster. To date, there has been little real-world data about the immunological effect of this strategy.
We compared the humoral- and cellular immune response before and after the third dose of BioNTech/Pfizer vaccine BNT162b2, following different prime-boost regimen in a prospective observational study. Humoral immunity was assessed by determining anti-SARS-CoV-2 binding antibodies using a standardized quantitative assay. In addition, neutralizing antibodies were measured using a commercial surrogate ELISA-assay. Interferon-gamma release was measured after stimulating blood-cells with SARS-CoV-2 specific peptides using a commercial assay to evaluate the cellular immune response.
We included 243 health-care workers who provided blood samples and questionnaires pre- and post- third vaccination. The median antibody level increased significantly after the third vaccination dose to 2663.1 BAU/ml vs. 101.4 BAU/ml (p < 0.001) before administration of the booster dose. This was also detected for neutralizing antibodies with a binding inhibition of 99.68% ± 0.36% vs. 69.06% ± 19.88% after the second dose (p < 0.001). 96.3% of the participants showed a detectable T-cell-response after the booster dose with a mean interferon-gamma level of 2207.07 mIU/ml ± 1905 mIU/ml.
This study detected a BMI-dependent antibody increase after the third dose of BNT162b2 following different vaccination protocols. All participants showed a significant increase in their immune response. This, in combination with the low rate of post-vaccination-symptoms underlines the potential beneficial effect of a BNT162b2-booster dose.
自 2020 年底推出各种针对 SARS-CoV-2 的疫苗以来，全球感染率持续攀升。这导致一些国家建立了第三针疫苗接种，即加强针。迄今为止，关于这种策略的免疫效果的实际数据很少。
我们在一项前瞻性观察研究中比较了不同的基础-加强免疫方案后，使用 BioNTech/Pfizer 疫苗 BNT162b2 进行第三针接种前后的体液和细胞免疫反应。通过使用标准化定量测定法来测定针对 SARS-CoV-2 的结合抗体来评估体液免疫。此外，还使用商业替代 ELISA 测定法来测量中和抗体。使用 SARS-CoV-2 特异性肽刺激血细胞后，通过商业测定法来测量干扰素-γ释放，以评估细胞免疫反应。
我们纳入了 243 名提供了接种前和接种后血样和问卷的医疗保健工作者。与接种加强针前的 101.4 BAU/ml 相比，第三针接种后抗体水平中位数显著升高至 2663.1 BAU/ml（p<0.001）。在第二针接种后中和抗体的结合抑制率也检测到类似的增加，为 99.68%±0.36% vs. 69.06%±19.88%（p<0.001）。在加强针接种后，96.3%的参与者显示出可检测的 T 细胞反应，平均干扰素-γ水平为 2207.07 mIU/ml±1905 mIU/ml。
本研究在不同疫苗接种方案后，检测到第三针 BNT162b2 接种后的 BMI 依赖性抗体增加。所有参与者的免疫反应均显著增加。结合接种后症状发生率低，这突出了 BNT162b2 加强剂量的潜在有益效果。
Zotero 插件
